Urologic Oncology Research Training Grant

描述（由申请人提供）：纪念斯隆-凯特琳癌症中心（MSKCC）泌尿肿瘤学T32研究培训计划的目标是培训合格的临床医生-科学家成为转化研究的独立研究者，并晋升为全职学术职位。泌尿肿瘤学的专门研究培训对于国家癌症研究所（NCI）消除癌症痛苦和死亡的使命至关重要：泌尿生殖系统癌症占所有非皮肤癌的近三分之一，占美国所有癌症死亡的10%。T32研究员通过与已建立的基础和转化研究科学家全职工作2年来获得生物医学研究的直接经验。研究员还需要参加结构化的多学科会议，并在MSKCC研讨会和国家会议上介绍他们的工作。T32导师代表外科，流行病学和生物统计学，医学，放射学和病理学部门，以及斯隆-凯特琳研究所的4个主要研究项目：细胞生物学，免疫学，分子生物学，分子药理学和化学。研究领域包括癌症遗传学;参与细胞增殖控制的信号和途径;蛋白质靶向;肿瘤免疫学，免疫治疗和临床治疗等。虽然研究员也可以进行1年的临床培训，但他们在研究期间没有临床责任，除非它是他们研究项目的组成部分。大多数T32研究员花费2.5至3.5年完成所有研究和临床培训。这个T32培训补助金将继续支持每年4名博士后研究员（通常是2名新学员和2名继续受训人员）。所有T32候选人必须具有医学博士学位，必须在研究生医学教育认证理事会（ACGME）批准的住院医师计划中完成泌尿外科培训，并且必须是符合董事会资格的泌尿科医生。T32研究员通常在PGY-6或PGY-7期间进入该计划。 相关性：MSKCC的T32泌尿肿瘤学课程培训合格的临床科学家，专注于消除泌尿系统癌症的痛苦和死亡，泌尿系统癌症占所有非皮肤癌的31%，占美国所有癌症死亡的10%。到目前为止，95%的毕业生已被录取到教师职位，并从事旨在了解和克服这些癌症的研究。

DESCRIPTION (provided by applicant): The goal of the T32 research training program in urologic oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) is to train qualified clinician-scientists to be independent investigators in translational research and to progress to full-time academic positions. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to eliminate suffering and death from cancer: genitourinary cancers comprise nearly one third of all non-skin cancers and cause 10% of all cancer deaths in the US. T32 fellows gain direct experience in biomedical research by working full-time for 2 years with established basic and translational research scientists. Fellows are also required to participate in structured, multidisciplinary conferences and to present their work at MSKCC seminars and national meetings. T32 preceptors represent the departments of Surgery, Epidemiology and Biostatistics, Medicine, Radiology, and Pathology, as well as 4 of the major research programs at the Sloan-Kettering Institute: Cell Biology, Immunology, Molecular Biology, and Molecular Pharmacology and Chemistry. Areas of research include cancer genetics; signals and pathways involved in the control of cell proliferation; protein targeting; tumor immunology, immunotherapy, and clinical therapeutics, among others. Although fellows may also undertake 1 year of clinical training, they have no clinical responsibilities during their research years unless it is integral to their research project. Most T32 fellows spend 2.5 to 3.5 years completing all research and clinical training. This T32 training grant will continue to support 4 postdoctoral fellows (typically 2 new and 2 continuing trainees) per year. All T32 candidates must have an MD, must have completed training in urology at a residency program approved by the Accreditation Council for Graduate Medical Education (ACGME), and must be board-eligible urologists. T32 fellows usually enter the program during PGY-6 or PGY-7. RELEVANCE: MSKCC's T32 program in urologic oncology trains qualified clinician-scientists for careers focused on eliminating suffering and death from urologic cancers, which comprise 31% of all non-skin cancers and cause 10% of all cancer deaths in the US. To date, 95% of the graduates have matriculated to faculty positions and are engaged in research aimed at understanding and overcoming these cancers.